Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: Introducing the Z-scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score

Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

Volumn 2, Issue , 2016, Pages 19-26

  Lim, Yen Ying ^a   Snyder, Peter J ^b,c   Pietrzak, Robert H ^d   Ukiqi, Albulene ^a   Villemagne, Victor L ^a,e   Ames, David ^a,f   Salvado, Olivier ^g   Bourgeat, Pierrick ^g   Martins, Ralph N ^h   Masters, Colin L ^a   Rowe, Christopher C ^a,e   Maruff, Paul ^a,i  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF RHODE ISLAND   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e AUSTIN HEALTH   (Australia)

^f NATIONAL AGEING RESEARCH INSTITUTE   (Australia)

^g CSIRO   (Australia)

^h EDITH COWAN UNIVERSITY   (Australia)

ⁱ Scientific Division   (Australia)

Author keywords

Amyloid; Cognitive composite; Cognitive decline; Neuropsychological assessment; Preclinical Alzheimer's disease

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E;

ADULT; ALZHEIMER DISEASE; ALZHEIMER DISEASE COOPERATIVE STUDY PRECLINICAL ALZHEIMER COGNITIVE COMPOSITE; APOE GENE; ARTICLE; COGNITION; COGNITIVE COMPOSITE SCORE; CONTROLLED STUDY; DISEASE ASSOCIATION; EPISODIC MEMORY COMPOSITE SCORE; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL ANALYSIS; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TEST; PATHOGENESIS; RATING SCALE; SCORING SYSTEM; SENSITIVITY ANALYSIS; TEST RETEST RELIABILITY; Z SCORES OF ATTENTION VERBAL FLUENCY AND EPISODIC MEMORY FOR NONDEMENTED OLDER OLDER ADULTS COMPOSITE SCORE;

EID: 84970916692     PISSN: None     EISSN: 23528729     Source Type: Journal    
DOI: 10.1016/j.dadm.2015.11.003     Document Type: Article

References (30)

1. Jack C.R., Wiste H.J., Lesnick T.G., Weigand S.D., Knopman D.S., Vemuri P., et al. Brain β-amyloid load approaches a plateau. Neurology 2013, 80:1-7.
2. Rowe C.C., Bourgeat P., Ellis K.A., Brown B., Lim Y.Y., Mulligan R., et al. Predicting Alzheimer disease with β-amyloid imaging: Results from the Australian imaging, biomarkers, and lifestyle study of ageing. Ann Neurol 2013, 74:905-913. for the AIBL Research Group.
3. Sperling R.A., Johnson K.A., Doraiswamy P.M., Reiman E.M., Fleisher A.S., Sabbagh M.N., et al. Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiol Aging 2013, 34:822-831.
4. Doraiswamy P.M., Sperling R.A., Johnson K., Reiman E.M., Wong T.Z., Sabbagh M.N., et al. Florbetapir F 18 amyloid PET and 36-month cognitive decline: A prospective multicenter study. Mol Psychiatry 2014, 19:1044-1051. for the AV45-A11 Study Group.
5. Lim Y.Y., Maruff P., Pietrzak R.H., Ames D., Ellis K.A., Harrington K., et al. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. Brain 2014, 137:221-231. for the AIBL Research Group.
6. Lim Y.Y., Villemagne V.L., Laws S.M., Pietrzak R.H., Snyder P.J., Ames D., et al. APOE and BDNF polymorphisms moderate amyloid β-related cognitive decline in preclinical Alzheimer's disease. Mol Psychiatry 2015, 20:1322-1328.
7. Mormino E.C., Betensky R.A., Hedden T., Schultz A.P., Ward A., Huijbers W., et al. Amyloid and APOE E4 interact to influence short-term decline in preclinical Alzheimer's disease. Neurology 2014, 82:1760-1767.
8. Villemagne V.L., Burnham S., Bourgeat P., Brown B., Ellis K.A., Salvado O., et al. Amyloid β deposition, neurodegeneration and cognitive decline in sporadic Alzheimer's disease: A prospective cohort study. Lancet Neurol 2013, 12:357-367. for the AIBL Research Group.
9. Dore V., Villemagne V.L., Bourgeat P., Fripp J., Acosta O., Chetelat G., et al. Cross-sectional and longitudinal analysis of the relationship between Aβ deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer's disease. JAMA Neurol 2013, 70:903-911.
10. Landau S.M., Mintun M.A., Joshi A.D., Koeppe R.A., Petersen R.C., Aisen P.S., et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol 2012, 72:578-586. for the Alzheimer's Disease Neuroimaging Initiative.
11. Jack C.R., Lowe V.J., Senjem M.L., Weigand S.D., Kemp B.J., Shiung M.M., et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008, 131:665-680.
12. Rowe C.C., Ellis K.A., Rimajova M., Bourgeat P., Pike K.E., Jones G., et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010, 31:1275-1283.
13. Reiman E.M., Langbaum J.B., Fleisher A.S., Caselli R.J., Chen K., Ayutyanont N., et al. Alzheimer's Prevention Initiative: A plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis 2011, 26(Supp 3):321-329.
14. Sperling R.A., Jack C.R., Aisen P.S. Testing the right target and right drug at the right stage. Sci Transl Med 2011, 3:111cm133.
15. Lacy M., Kaemmerer T., Czipri S. Standardized mini-mental state examination scores and verbal memory performance at a memory center: Implications for cognitive screening. Am J Alzheimers Dis Other Demen 2015, 30:145-152.
16. Lim Y.Y., Ellis K.A., Harrington K., Pietrzak R.H., Gale J., Ames D., et al. Cognitive decline in adults with mild cognitive impairment and high Aβ amyloid: Prodromal Alzheimer's disease?. J Alzheimers Dis 2013, 33:1167-1176. for the AIBL Research Group.
17. Spencer R.J., Wendell C.R., Giggey P.P., Katzel L.I., Lefkowitz D.M., Siegel E.L., et al. Psychometric limitations of the mini-mental state examination among nondemented older adults: An evaluation of neurocognitive and magnetic resonance imaging correlates. Exp Aging Res 2013, 39:382-397.
18. Donohue M.C., Sperling R.A., Salmon D.P., Rentz D.M., Raman R., Thomas R.G., et al. The preclinical Alzheimer cognitive composite: Measuring amyloid-related decline. JAMA Neurol 2014, 71:961-970.
19. Langbaum J.B., Hendrix S.B., Ayutyanont N., Chen K., Fleisher A.S., Shah R.C., et al. An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease. Alzheimers Dement 2014, 10:666-674.
20. Kantarci K., Lowe V.J., Przybelski S.A., Senjem M.L., Weigand S.D., Ivnik R.J., et al. Magnetic resonance spectroscopy, β-amyloid load, and cognition in a population-based sample of cognitively normal older adults. Neurology 2011, 77:951-958.
21. Kryscio R.J. Secondary prevention trials in Alzheimer disease: The challenge of identifying a meaningful end point. JAMA Neurol 2014, 71:947-949.
22. Insel P.S., Mattsson N., Mackin R.S., Kornak J., Nosheny R., Tosun-Turgut D., et al. Biomarkers and cognitive endpoints to optimize trials in Alzheimer's disease. Ann Clin Transl Neurol 2015, 2:534-547.
23. Ellis K.A., Bush A.I., Darby D., De Fazio D., Foster J., Hudson P., et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: Methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int Psychogeriatr 2009, 21:672-687. for the AIBL Research Group.
24. Clark C.M., Schneider J.A., Bedell B.J., Beach T.G., Bilker W.B., Mintun M.A., et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011, 305:275-283. for the AV45-A07 Study Group.
25. Vandenberghe R., Van Laere K., Ivanoiu A., Salmon E., Bastin C., Triau E., et al. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial. Ann Neurol 2010, 68:319-329.
26. Jedynak B.M., Lang A., Liu B., Katz E., Zhang Y., Wyman B.T., et al. A computational neurodegenerative disease progression score: Method and results with the Alzheimer's Disease Neuroimaging Initiative cohort. Neuroimage 2012, 63:1478-1486. for the Alzheimer's Disease Neuroimaging Initiative.
27. Lim Y.Y., Ellis K.A., Pietrzak R.H., Ames D., Darby D., Harrington K., et al. Stronger effect of amyloid load than APOE genotype on cognitive decline in healthy older adults. Neurology 2012, 79:1645-1652. for the AIBL Research Group.
28. Mills S.M., Mallmann J., Santacruz A.M., Fuqua A., Carril M., Aisen P.S., et al. Preclinical trials in autosomal dominant AD: Implementation of the DIAN-TU trial. Rev Neurol 2013, 169:737-743.
29. Jurica P.J., Leitten C.L., Mattis S. DRS-2 dementia rating scale-2: professional manual 2004, Psychological Assessment Resources, Odessa, FL.
30. Crane P.K., Narasimhalu K., Gibbons L.E., Mungas D.M., Haneuse S., Larson E.B., et al. Item response theory facilitated cocalibrating cognitive tests and reduced bias in estimated rates of decline. J Clin Epidemiol 2008, 61:1018-1027.